Closing Price: 37 cents (June 29)
Six-Month Stock Performance: -67.8%Received Nasdaq Notice: June 17 Management's Expected Action: The biopharmaceutical company has until Dec. 14 to regain compliance, which is a tough task as the stock has dropped from a 52-week high of $2.37 all the way to a 52-week low, where it currently rests. Supply-side economist Arthur Laffer resigned from the company's board in March, when the stock still traded above $1. Oxigene shares plunged in early June after the company presented data on clinical studies at the American Society of Clinical Oncology (ASCO) annual meeting. Oxigene said it will "consider various options available to the company if its common stock does not trade at a level that is likely to regain compliance," but didn't offer any specific plans.